The results of clinical studies on ASK1 inhibitors in NAFLD are gradually emerging, but their clinical application in liver I/R injury is relatively inadequate with regard to their target diversity. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatotic liver disease.